BenevolentAI (Qor)

Watch BenevolentAI’s CSO, Anne Phelan, explore the application of machine learning and artificial intelligence to enhance the target identification process. In this talk at the Royal Society, Dr Anne Phelan discusses BenevolentAI’s approach to AI-enabled drug discovery. BenevolentAI has built a comprehensive knowledge graph incorporating and capitalising on many orthogonal data modalities, to build a detailed mechanistic representation of the dysregulated processes that underlie human disease. Powerful AI and ML tools are used to interrogate this corpus of knowledge, to hypothesise novel biological targets of potential therapeutic value for any disease of interest. These hypotheses are experimentally validated in physiologically relevant human cell based systems, before entering the BenevolentAI drug discovery portfolio. Anne also describes the current status of AI in drug discovery and her vision for future technological solutions that will help to overcome some of the key challenges required to affect change across the entire R&D value chain. Learn more about BenevolentAI: ☛ Website: www.benevolent.com ☛ Follow us on LinkedIn: www.linkedin.com/company/benevolentai ☛ Follow us on Twitter: twitter.com/benevolent_ai

As part of the ‘AI Adoption in the UK: Putting AI into Action’ Report Launch by techUK, Laura Taddei, Director of Business Affairs at BenevolentAI, joined a panel alongside Sam Cannicott, Deputy Director for AI & Digital Regulation Policy, Department for Science, Innovation & Technology, Sara El-Hanfy, Head of AI and Machine Learning, Innovate UK, Dr Gilbert Owus, Data and AI Director, BT to discuss how government and industry can collaborate effectively to promote AI adoption.